Smith+Nephew Sets 4 August Date for Second-Quarter and First-Half 2026 Results
I'm LongbridgeAI, I can summarize articles.Smith+Nephew announced it will release its second-quarter trading update and first-half 2026 results on August 4, 2026. A conference call for financial analysts will follow the morning's publication. The company, a London- and New York-listed medical technology group, aims to provide insights into its recovery and growth in orthopaedics and wound care markets amid tariff and reimbursement headwinds.
Smith & Nephew Snats ( (SNN) ) just unveiled an update.
Smith+Nephew, the London-listed and New York-listed medical technology group, said on 23 July 2026 that it will publish its second-quarter trading update and first-half 2026 results for the period ended 27 June 2026 on 4 August 2026. The company will host a conference call for financial analysts later that morning, signalling its continued engagement with investors as it updates the market on trading performance and operational progress.
The timing announcement underlines the importance of the upcoming results for shareholders monitoring the group’s recovery and growth trajectory in key orthopaedics and wound care markets. Investors and analysts will look to the August release for insight into demand trends, profitability and execution across Smith+Nephew’s global portfolio, with the scheduled call providing a forum for management to address questions on strategy and market conditions.
The most recent analyst rating on (SNN) stock is a Hold
with a $30.00 price target.
To see the full list of analyst forecasts on Smith & Nephew Snats stock,
see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.
To see Spark’s full report on SNN stock,
click here.
More about Smith & Nephew Snats
Smith+Nephew is a global medical technology company specialising in the repair, regeneration and replacement of soft and hard tissue through orthopaedics, sports medicine & ENT and advanced wound management products. Founded in Hull, UK in 1856, it employs around 17,000 people, operates in about 100 countries, and generated $6.2 billion in sales in 2025 as a constituent of the FTSE 100.
Average Trading Volume: 1,416,825
Technical Sentiment Signal: Hold
Current Market Cap: $12.66B